Litigation Details for Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2015)

« Back to Dashboard

Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2015)

Docket	1:15-cv-00109	Date Filed	2015-01-29
Court	District Court, D. Delaware	Date Terminated	2015-12-15
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,501,730
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-29				External link to document
2015-01-28	28		Initial Invalidity Contentions for U.S. Patent No. 8,501,730 filed by Par Pharmaceutical Inc..(Lester… 15 December 2015 1:15-cv-00109 830 Patent None District Court, D. Delaware	External link to document
2015-01-28	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,753,677; 8,501,730 B2;. (els) (Entered… 15 December 2015 1:15-cv-00109 830 Patent None District Court, D. Delaware	External link to document
2015-01-28	69		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,753,677; 8,501,730 B2. (Attachments… 15 December 2015 1:15-cv-00109 830 Patent None District Court, D. Delaware	External link to document

Otsuka Pharmaceutical v. Apotex: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: October 10, 2026

Otsuka Pharmaceutical’s Hatch-Waxman case against Apotex concerned aripiprazole, the active ingredient in Abilify tablets. The principal patent at issue was U.S. Patent No. 8,017,615. Apotex filed an abbreviated new drug application and delivered a Paragraph IV certification challenging the patent. The U.S. District Court for the District of Delaware ruled against Otsuka on validity, and the Federal Circuit later affirmed in a nonprecedential Rule 36 judgment. The case removed the asserted patent as a barrier to generic aripiprazole entry. (Otsuka Pharmaceutical Co. v. Apotex Inc., 2017; U.S. District Court for the District of Delaware, 2015-2017)

What was Otsuka Pharmaceutical v. Apotex about?

The litigation was a patent infringement action under the Hatch-Waxman Act. Otsuka alleged that Apotex’s proposed generic aripiprazole tablets would infringe patent claims covering an aripiprazole pharmaceutical preparation.

Item	Detail
Case	Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-00109
Filing date	February 6, 2015
Plaintiff	Otsuka Pharmaceutical Co. Ltd.
Defendants	Apotex Inc. and related Apotex entities
Product	Aripiprazole tablets
Reference product	Abilify
Regulatory pathway	ANDA under the Hatch-Waxman Act
Primary patent	U.S. Patent No. 8,017,615
Federal Circuit citation	Otsuka Pharmaceutical Co. v. Apotex Inc., 678 F. App'x 971 (Fed. Cir. 2017)
Final appellate disposition	Affirmed under Federal Circuit Rule 36

The case was separate from Otsuka’s earlier litigation over the basic aripiprazole compound patent, U.S. Patent No. 5,006,528. That compound patent expired before the Apotex case was filed. The 2015 action therefore focused on a later patent that Otsuka sought to use as an additional barrier to generic competition.

What patent protected Abilify in the Apotex litigation?

The principal asserted patent was U.S. Patent No. 8,017,615, which concerned an aripiprazole-containing pharmaceutical preparation.

The patent was part of Otsuka’s secondary patent estate for aripiprazole. Secondary patents generally target formulation, dosage-form, manufacturing, crystalline-form, or other product-specific characteristics after the basic active-ingredient patent has expired.

The litigation record identifies the '615 patent as the patent challenged by Apotex in the ANDA case. The dispositive issue was whether the asserted claims were valid, particularly in view of obviousness.

Patent profile

Patent	Technology focus	Litigation relevance
U.S. 5,006,528	Aripiprazole compound	Earlier basic compound patent; not the central patent in the 2015 Apotex action
U.S. 8,017,615	Aripiprazole pharmaceutical preparation	Main patent asserted against Apotex
Later Otsuka patents	Formulation and product-specific subject matter	Potentially relevant to other Abilify products and later generic disputes, but not the principal basis of the Apotex appellate decision

The nominal patent term for the '615 patent extended materially beyond the expiration of the basic aripiprazole compound patent. Its invalidity therefore had commercial significance: it prevented Otsuka from using the patent as a post-compound-patent exclusion right against Apotex.

When did Otsuka sue Apotex?

Otsuka filed the complaint on February 6, 2015, in the District of Delaware. The action followed Apotex’s ANDA filing and Paragraph IV challenge.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. The certification permits the patent holder to file an infringement suit before FDA approval. A timely suit ordinarily triggers a statutory stay of FDA approval for up to 30 months, unless the case is resolved earlier or the court orders otherwise. (21 U.S.C. § 355(j)(5)(B)(iii))

The filing of the case did not establish infringement. It initiated the patent dispute and allowed the court to determine whether the patent could block FDA approval of Apotex’s ANDA.

What were the principal legal issues?

The central issue was patent validity, with obviousness providing the decisive legal framework.

Infringement

Otsuka alleged that Apotex’s proposed aripiprazole product would meet the limitations of the asserted claims. In Hatch-Waxman litigation, the act of filing an ANDA with a Paragraph IV certification is treated as an artificial act of infringement under 35 U.S.C. § 271(e)(2).

The infringement issue is assessed against the ANDA product and its proposed labeling, not against later commercial conduct. The court therefore analyzed whether the product described in Apotex’s ANDA would fall within the patent claims.

Obviousness

Apotex challenged the validity of the '615 patent under 35 U.S.C. § 103. The analysis required the court to consider:

1. The scope and content of the prior art.
2. Differences between the prior art and the claimed invention.
3. The level of ordinary skill in the relevant field.
4. Objective indicia of nonobviousness, where supported by the record.

The Federal Circuit’s reported disposition was a Rule 36 affirmance. That procedure affirms the lower court’s judgment without issuing a full written merits opinion. The appellate decision therefore confirms the result but provides limited independent analysis of the patent’s claim construction or obviousness reasoning. (Otsuka Pharmaceutical Co. v. Apotex Inc., 678 F. App'x 971 (Fed. Cir. 2017))

How did the court resolve the litigation?

The case ended in Apotex’s favor on the asserted patent. The district court held the relevant claims of the '615 patent invalid, and the Federal Circuit affirmed.

The practical result was that Otsuka could not enforce the asserted patent to prevent Apotex’s proposed generic aripiprazole product from obtaining FDA approval or entering the market after satisfaction of regulatory requirements.

The Federal Circuit’s Rule 36 affirmance left the district court’s judgment in place. Because there was no precedential appellate opinion explaining a new legal rule, the principal business consequence was case-specific: the asserted Otsuka patent did not provide an enforceable exclusion right against Apotex.

What was the litigation timeline?

Date	Event
February 6, 2015	Otsuka filed the Delaware infringement action against Apotex
2015-2016	The parties litigated the validity and infringement issues arising from Apotex’s Paragraph IV ANDA filing
2016	The district court entered judgment resolving the asserted patent in Apotex’s favor
2017	The Federal Circuit affirmed in a Rule 36 decision
After affirmance	The '615 patent no longer operated as an enforceable barrier against Apotex’s proposed aripiprazole entry

The public appellate citation establishes the Federal Circuit disposition. The district-court docket supplies the underlying procedural history and judgment record.

What was the Orange Book status of Abilify?

Abilify was approved by FDA as an aripiprazole product. Otsuka’s Orange Book strategy included the original compound patent and later patents associated with aripiprazole products. The Apotex case concerned a later patent rather than the original compound patent.

Orange Book listing and patent enforceability are separate questions:

• FDA lists patents submitted by the NDA holder that meet the statutory listing requirements.
• A listed patent may be challenged through a Paragraph IV certification.
• A listed patent can later be held invalid or not infringed.
• An Orange Book listing does not establish that the patent will survive litigation.

The Apotex result illustrates the distinction. The asserted patent could be listed and could trigger Hatch-Waxman litigation, but the court ultimately held it unavailable as an enforceable exclusion right against Apotex.

FDA’s Orange Book identifies listed patents and regulatory exclusivity for approved drug products. It does not replace the court’s validity judgment. (U.S. Food and Drug Administration, 2024)

Did the case involve a biosimilar challenge?

No. The case involved a small-molecule generic drug, not a biologic and not a biosimilar.

Apotex proceeded through an ANDA for aripiprazole tablets. The relevant regulatory framework was the Hatch-Waxman Act, including Paragraph IV certification. Biosimilar litigation proceeds under the Biologics Price Competition and Innovation Act and involves a biologics license application, patent-information exchange, and different exclusivity concepts.

The absence of biosimilar risk is commercially important. The competitive threat in this case was conventional generic substitution for aripiprazole tablets.

What generic entry risks did Otsuka face?

Otsuka faced three principal risks.

Loss of the secondary patent barrier

The invalidity ruling eliminated the asserted '615 patent as a blocking right against Apotex. This reduced the value of Otsuka’s post-compound-patent patent strategy.

Competitive price erosion

Once generic aripiprazole products entered, pharmacy substitution and payer contracting placed pressure on Abilify pricing. Aripiprazole had substantial commercial exposure because Abilify was a major atypical antipsychotic product with broad use in schizophrenia, bipolar disorder, and adjunctive treatment of major depressive disorder.

Reduced litigation leverage

A successful Paragraph IV challenge can produce a market-entry outcome that affects not only the named generic applicant but also the branded company’s negotiating position with other ANDA filers. The loss of one important patent can weaken settlement leverage across the generic field.

How strong was Otsuka’s aripiprazole patent estate?

The estate had strong historical value but weaker durability after compound-patent expiry.

Estate layer	Strategic value	Risk
Basic aripiprazole compound patent	Highest protection for the active ingredient	Expired before the Apotex action
Formulation and preparation patents	Extended potential exclusivity	Vulnerable to obviousness and claim-scope attacks
Method-of-use patents	Can target specific indications or dosing regimens	More difficult to enforce against products with narrow or carved-out labeling
Product-specific patents	May protect a defined dosage form or manufacturing characteristic	Dependent on claim construction and proof that the ANDA product meets each limitation
Regulatory exclusivity	Can delay approval independently of patent validity	Limited duration and separate from patent enforceability

The Apotex decision demonstrates the risk of relying on later-arising formulation or preparation patents to replace a lapsed compound patent. Such patents may have longer nominal terms, but their commercial value depends on claim validity, claim coverage of the ANDA product, and the availability of noninfringing design-arounds.

Did the parties enter a settlement agreement?

The reported Federal Circuit disposition does not establish a publicly reported settlement as the basis for termination. The case proceeded to a judgment that was affirmed on appeal.

A judgment-based resolution differs from a confidential Hatch-Waxman settlement. A settlement may preserve commercial timing arrangements while leaving patent validity formally undecided. Here, the reported Rule 36 affirmance indicates that the lower-court judgment remained operative.

No separate settlement terms should be inferred from the appellate affirmance.

What manufacturing and formulation barriers remained?

The invalidity of the asserted '615 patent did not eliminate every possible technical barrier to generic manufacture. Apotex still needed to satisfy FDA requirements for:

• Pharmaceutical equivalence.
• Bioequivalence.
• Content uniformity.
• Dissolution performance.
• Stability.
• Manufacturing controls.
• Labeling compliance.
• Current good manufacturing practice requirements.

Those regulatory requirements are not substitutes for a valid patent. They can delay or prevent approval of a particular ANDA, but they do not create branded exclusivity in the same manner as an enforceable patent.

For the branded company, formulation patents remain most valuable when they claim a product attribute that is difficult to avoid and easy to prove from the ANDA or commercial product. Broad, predictable claims that read directly on routine generic formulations face greater obviousness and design-around risk.

What was the commercial significance of the Apotex judgment?

The decision weakened Otsuka’s ability to extend Abilify exclusivity through the asserted secondary patent. The basic compound patent had already reached the end of its effective life, so the '615 patent represented a later opportunity to control generic entry.

For Apotex, the judgment removed a patent-based obstacle to its ANDA pathway. For Otsuka, it reduced the value of the remaining oral aripiprazole patent estate and increased exposure to generic price competition.

The case also illustrates a recurring pharmaceutical litigation pattern: a branded company may obtain substantial commercial protection from a compound patent, but later patents must survive separate validity challenges. A court’s invalidity ruling against a formulation or preparation patent can materially change market timing even when the product remains FDA approved and the patent remains listed or was previously listed.

Key Takeaways

• Otsuka sued Apotex in the District of Delaware on February 6, 2015.
• The action arose from Apotex’s Paragraph IV challenge to an aripiprazole patent.
• U.S. Patent No. 8,017,615 was the principal patent at issue.
• The district court ruled the asserted claims invalid.
• The Federal Circuit affirmed in a Rule 36 judgment in 2017.
• The case involved a small-molecule ANDA, not a biosimilar application.
• The ruling removed the asserted patent as a barrier to Apotex’s generic aripiprazole entry.
• The result reduced the value of Otsuka’s post-compound-patent exclusivity strategy for Abilify.
• Orange Book listing did not prevent the asserted patent from being invalidated.
• The decision did not establish a publicly reported settlement agreement.

FAQs

What drug was involved in Otsuka Pharmaceutical v. Apotex?

The case involved aripiprazole, the active ingredient in Otsuka’s Abilify tablets.

Which Otsuka patent did Apotex challenge?

Apotex challenged U.S. Patent No. 8,017,615, an aripiprazole pharmaceutical-preparation patent.

Did Apotex win the aripiprazole patent case?

Yes. The district court resolved the asserted patent in Apotex’s favor, and the Federal Circuit affirmed.

Was Otsuka v. Apotex a Paragraph IV lawsuit?

Yes. The litigation arose from Apotex’s Paragraph IV certification in connection with its aripiprazole ANDA.

Did the decision affect biosimilar competition?

No. The case concerned a conventional generic drug under the Hatch-Waxman Act and did not involve a biologic or biosimilar.

References

1. Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc., No. 1:15-cv-00109, U.S. District Court for the District of Delaware (2015-2017).

2. Otsuka Pharmaceutical Co. v. Apotex Inc., 678 F. App'x 971 (Fed. Cir. 2017).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov

4. Hatch-Waxman Act, 21 U.S.C. § 355(j).

5. 35 U.S.C. § 271(e)(2).